SECAUCUS, N.J., Feb. 1, 2021 /PRNewswire/ -- Quest Diagnostics
(NYSE: DGX), the world's leading provider of diagnostic
information services, today announced that it has been selected as
one of FORTUNE's World's Most Admired Companies in
2021 for the seventh consecutive year.
"We are honored for the seventh consecutive year to receive this
award, which belongs to our nearly 50,000 employees,"
said Steve Rusckowski, Chairman, CEO and President.
"Over the past year they stepped up when our country needed them
most by developing COVID-19 tests, building test capacity,
innovating new testing models with our retail partners,
transporting specimens, delivering results, and, of course,
supporting our customers. They are heroes."
The annual survey designated Quest Diagnostics as one of only
five companies to attain Most Admired status in the "Health
Care: Pharmacy and Other Services" industry category.
FORTUNE's "World's Most Admired Companies" list is based on
surveys of 670 companies from 30 countries, asking executives,
directors, and analysts to rate enterprises within their own
industry on nine criteria, from investment value and quality of
management and products to social responsibility and ability to
attract talent.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve
health outcomes. Derived from the world's largest database of
clinical lab results, our diagnostic insights reveal new avenues to
identify and treat disease, inspire healthy behaviors and improve
health care management. Quest Diagnostics annually serves one in
three adult Americans and half the physicians and hospitals
in the United States, and our nearly 50,000 employees
understand that, in the right hands and with the right context, our
diagnostic insights can inspire actions that transform
lives. www.QuestDiagnostics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-named-one-of-2021-worlds-most-admired-companies-by-fortune-magazine-for-seventh-consecutive-year-301219172.html
SOURCE Quest Diagnostics